Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Entry archive:

Joe Jimenez, CEO of Swiss drug maker Novartis, gestures during an interview with Reuters at the company's headquarters in Basel in this March 19, 2014 file photo. (ARND WIEGMANN/REUTERS)
Joe Jimenez, CEO of Swiss drug maker Novartis, gestures during an interview with Reuters at the company's headquarters in Basel in this March 19, 2014 file photo. (ARND WIEGMANN/REUTERS)

Novartis, GSK, Lilly sign multibillion-dollar deals to trade business units Add to ...

Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally.

The Basel, Switzerland-based company said it has agreed to buy GlaxoSmithKline plc’s cancer-drug business for $14.5-billion, plus up to $1.5-billion more if certain milestones are met, and to divest most of its vaccines business to GSK for $7.1-billion, plus royalties.

More Related to this Story

The two drugmakers also are creating a new consumer health care business through a joint venture. It combines Novartis’ over-the-counter drug business with GSK’s consumer business to create a new entity that would generate $10-billion a year in revenue. Novartis would own 36.5 per cent of the new business, focusing on pain management, coughs and colds and dermatology.

All the deals between Novartis and GSK are timed to close simultaneously.

Separately, Novartis said it will sell off its animal health division to U.S.-based Eli Lilly & Co. for about $5.4-billion.

In a statement, Novartis CEO Joseph Jimenez said the deals mark “a transformational moment” for the company by refocusing its business around three core strengths: innovative drugs, eye care and generics.

“They also improve our financial strength, and are expected to add to our growth rates and margins immediately,” he said.

The oncology business that Novartis is picking up from GSK had revenue of $1.6-billion and a 20 per cent growth rate last year, Jimenez told reporters in a conference call.

And the Swiss company said its flu business, which is not part of the sale to U.K.-based GSK, would be divested in another pending deal, but it did not provide more specifics.

Taken together, the deals will reduce Novartis’ sales by about $4-billion, from $60-billion down to $56-billion, Jimenez said, but the company’s “absolute profit goes up and that’s partly because we’re acquiring the oncology products and we are divesting products that have lower profit.”

The transactions affect some 15,000 of the company’s 135,000 employees globally, he said, and “they will move with the divestitures or into that joint venture.”

Novartis employs about 2,000 people in Ontario and Quebec.

Jimenez, however, said Novartis won’t fire anyone. All Novartis employees whose units are being sold off “will be fully transferred to the new owners,” he said.

With files from The Canadian Press

Follow us on Twitter: @GlobeBusiness

 
  • GSK-N
  • LLY-N
  • NVS-N
Live Discussion of GSK on StockTwits
More Discussion on GSK-N
Live Discussion of LLY on StockTwits
More Discussion on LLY-N
Live Discussion of NVS on StockTwits
More Discussion on NVS-N

More Related to this Story

Topics:

In the know

Most popular video »

Highlights

More from The Globe and Mail

Most Popular Stories